Phenylhydroxylamine: Role in Aniline-Associated Splenic Oxidative Stress and Induction of Subendocardial Necrosis. Khan, M. R, Green, S. M., Ansari, G. A. S., and Boor, P. J. (1998). Toxicol. Sci. 42, 64-71. To elucidate the role of iV-phenyihydroxylamine (PHA, N-hydroxylated metabolite of aniline) in the selective toxidty of aniline to the spleen, dose-dependent studies were conducted with PHA in rats. Male Sprague-Dawley rats were given four doses each (1 dose/day) of 0.025, 0.05, 0.1, or 0.2 mmol/kg PHA in 0.5 ml of aqueous agar (0.25%) by gavage. The control animals received an equal volume of vehicle only. The animals were euthanized 24 h following the last dose. PHA toxicity in the blood was evident from a dose-dependent increase of methemoglobin. The most affected organ was spleen, which appeared dark and enlarged (splenomegaly) and showed increased spleen-to-body weight ratios, which were 28,40, 66, and 87% at PHA doses of 0.025, 0.05, 0.1, and 02 mmol/kg, respectively. Splenic lipid peroxidation (malondialdehyde content) was higher in all PHA-treated groups, whereas splenic protein oxidation (carbonyl content) increased in only the 0.05,0.1, and 0.2 mmol/kg groups. The total iron content in the spleen also showed increases of 88,135,168, and 209% at PHA doses of 0.025, 0.05,0.1, and 0.2 mmol/kg, respectively. These biochemical changes were accompanied by a dosedependent vascular congestion in the spleen, a characteristic feature of aniline toxicity. Although the ratio of organ to body weight increased for both testes and heart at the highest dose, striking morphological changes were observed only in heart. The cardiac lesions consisted of a both acute and resolving multifocal subendocardial necrosis involving predominently the left ventricle. Our results suggest that PHA is a splenotoxin and thus contributes to the toxicity of aniline, while at a high dose, it is also cardiotoxic, perhaps due to anoxia associated with the marked methemoglobinemia. These results further support the involvement of oxidative stress in the splenotoxicity of aniline which may be caused by its reactive metabolites) SUCh as PHA.
methemoglobinemia and hemolytic anemia (Jenkins et al., 1972; Harrison and Jollow, 1986; Kim and Carlson, 1986; Khan et al., 1993 Khan et al., , 1995a and by the development of splenomegaly, splenic hyperplasia, siderosis, fibrosis, and a variety of sarcomas, most commonly fibrosarcomas, following chronic exposure in rats (Goodman et al., 1984; Weinberger et al., 1985; Bus and Popp, 1987; Khan et al, 1993 Khan et al, , 1995a Khan et al, , 1997a . Even though a number of studies have documented anilineinduced erythrocyte damage, little effort has been made toward delineation of aniline-induced splenic toxicity. Understanding the mechanism(s) of this selective splenotoxic response is important because of potential human exposure to aniline and other structurally related chemicals and drugs.
Aniline is extensively metabolized to a variety of oxidized products. Oxidation of the amino group in aniline results in the formation of /V-hydroxyaniline (phenylhydroxylamine, PHA), which can be further oxidized to nitrosobenzene (NB) (Eyer et al., 1980) . On the other hand, ring hydroxylation results in the formation of 2-and 4-aminophenols (Kao et al., 1978) . Since erythrocytes are highly sensitive to aniline insult, the emphasis so far has been to identify aniline metabolites responsible for methemoglobin formation and erythrocyte damage Jollow, 1986, 1987; Eckert, 1988; Eyer, 1988) . It is possible that the metabolites of aniline may also be responsible for selective damage to the spleen. Our pilot studies using equimolar doses (0.5 mmol/kg) of aniline metabolites indicated that PHA is splenotoxic compared to 2-and 4-aminophenols in rats. This is also supported by the fact that PHA, which is interconvertible with NB in blood (Kiese, 1966) , is the most active metabolite in causing aniline-induced hemolytic anemia (Harrison and Jollow, 1986; Bradshaw et al., 1995) and methemoglobinemia (Kiese, 1966; Harrison and Jollow, 1987) . Therefore, in order to systematically evaluate the contribution of PHA to the splenotoxicity of aniline, a dose-response study of PHA was conducted in rats.
Aniline, an extensively used industrial chemical, is toxic to the hematopoietic system. The toxicity is characterized by cals. Inc. (St. Louis, MO). Agar was procured from Difco (Detroit, MI). All other reagents used in this study were of analytical grade.
Animals. Male Sprague-Dawley rats (-200 g), obtained from Harlan Sprague-Dawley (Indianapolis, IN), were housed in wire-bottom cages over absorbent paper with free access to tap water and Purina lab chow. The rats were acclimatized in a controlled environment animal room (temperature, 22°C; relative humidity, 50%; photoperiod, 12-h light/dark cycle) for 7 days prior to the treatment.
Dose-response studies with phenylhydroxylamine. Male Sprague-Dawley rats, in groups of five, received four doses each (one dose/day) of 0.025, 0.05, 0.1, or 0.2 mmol/kg of PHA in 0.5 ml of 0.25% agar by gavage. Animals receiving only agar solution served as controls.
The animals from all the groups were euthanized 24 h following the last dose. Animals were anesthetized with ether, blood (5-7 ml) was withdrawn from the inferior vena cava, and an aliquot of blood was quickly transferred to tubes containing EDTA for hematological analysis and methemoglobin determination, while the remaining blood was used to obtain serum. All major organs (spleen, lung, liver, heart, kidney, thymus, and testes) were removed immediately, blotted, weighed, and stored at -80°C until further analysis.
Blood analysis. Red blood cell (RBC) count, white blood cell (WBC) count, hemoglobin, hematocrit (HCT), platelets, and leukocyte differential counts were determined on a STKS Coulter Counter (Coulter Electronics, Inc., Hialeah, FL) at the Hematology Laboratory of the Department of Pathology, University of Texas Medical Branch. Methemoglobin in the blood samples was determined according to the procedure of Harrison and Jollow (1986) .
Lipid peroxidation. Lipid peroxidation in the spleen homogenates was determined according to the method of Ohkawa et al. (1979) by measuring the formation of thiobarbituric acid-reactive substances (TBARS) and using 1,1,3,3-tetramethoxypropane as standard. Protein content in the spleen homogenates was determined according to Lowry et al. (1951) . The lipid peroxidation results arc expressed as nmol malondialdehyde (MDA)/mg protein.
Protein oxidation. Protein oxidation in the splenic homogenates of control and treated rats was measured by reducing carbonyl groups with NaB 3 H 4 as described by Lenz et al. (1989) , with slight modifications reported in our earlier study (Khan et al, 1997a) .
Quantitation of splenic iron. Iron content in the control and PHA-treated rats was analyzed according to Alcock (1987) as detailed earlier (Khan et al., 1995b (Khan et al., , 1997a . The results are expressed as micrograms iron (Fe) per gram wet tissue.
Histology.
A portion of each tissue was fixed in 10% neutral-buffered Formalin for standard histological processing. Paraffin sections were cut and stained with hematoxylin and eosin (H&E) for general morphological evaluation. Sections of the spleen, liver, and heart were also stained with Perl's Prussian blue for iron.
Statistical analysis of the data. Results are presented as means ± SD of five animals in each group. Statistical comparisons of the data for different groups were done by analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test. The accepted level of significance was set at p £ 0.05.
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RESULTS
Hematological Analysis
PHA treatment showed only marginal decreases (statistically insignificant) in the RBC counts, hemoglobin content, and HCT at all doses (data not included). Platelet counts were similar in all groups. WBC counts were mostly higher; however, only the values at 0.2 mmol/kg (8.08 ± 1.71 X 10 6 /ml for control vs 16.73 ± 1.87 X 10 6 /ml for PHA group) were significantly different when compared to the control. Admin-
Dose ( istration of PHA resulted in a dose-dependent increase in the methemoglobin content of the blood and a maximum increase of ~18-fold (1651%) was observed at 0.2 mmol/kg of PHA ( Fig. 1) .
Effect of PHA on Body Weight Gain and Ratios of Organ Weight to Body Weight
Changes in the body weight gain and ratios of organ weight to body weight of rats treated with various doses of PHA are presented in Table 1 . Body weight gain in animals treated with 0.025 and 0.05 mmol/kg PHA was comparable to that in the controls. However, at higher doses (i.e., 0.1 and 0.2 mmol/kg), the gain was significantly lower. The organ weight most affected was that of the spleen (absolute weight 0.71 ± 0.05 g for the control group vs 0.86 ± 0.10, 0.95 ± 0.06, 1.09 ± 0.12, and 1.17 ± 0.05 g for the 0.025, 0.05, 0.1, and 0.2 mmol/kg PHA groups, respectively) which appeared dark and enlarged (splenomegaly). The increases in the spleen-to-body-weight ratios were 28, 40, 66, and 87% at PHA doses of 0.025, 0.05, 0.1, and 0.2 mmol/kg, respectively. Liver showed significant decreases in this ratio at the higher doses. Heart of the highdose group showed a slight increase in absolute weight (1.00 ± 0.09 g for PHA group vs 0.92 ± 0.05 g for controls), and heart and testes showed significant increases in the ratio of organ/ body weight at the highest dose.
Effect of PHA Treatment on Splenic Lipid Peroxidation and Protein Oxidation
Lipid peroxidation, expressed as nmol MDA/mg protein, showed consistent increases at all the PHA doses with a maximum increase of 44% at 0.2 mmol/kg (Fig. 2) . Protein oxidation, measured as nmol carbonyl/mg protein, showed significantly increased carbonyl content in the splenic homogenates at most of the doses (except 0.025 mmol/kg group) used in this study (Fig. 3) .
Splenic Iron Content
PHA treatment resulted in a dose-dependent increase in the total iron content of the spleen. The increases were 88, 135, 168, and 209% for 0.025, 0.05, 0.1, and 0.2 mmol/kg doses, respectively (Fig. 4) .
Morphological Evaluation
The spleen and heart showed distinct lesions. Splenic lesions displayed a pattern of vascular congestion (Fig. 5) that was similar to lesions observed in aniline-treated animals in our previous studies (Khan et ai, 1995a (Khan et ai, , 1997a . The severity of splenic lesions was dose-dependent, based on the degree of sinusoidal congestion. There was no apparent increase in hematopoietic precursor cells in the spleen. A slight, diffuse accumulation of hemosiderin was found in the red pulp using Perl's stain. The splenic capsule appeared normal, and there was no apparent change in the ratio of red pulp/white pulp.
Heart lesions were only observed in the 0.2 mmol/kg PHA group (three of four animals). These lesions consisted of multifocal acute and resolving subendocardial necrosis involving predominantly the left ventricle (Fig. 6) . In one heart, necrosis involved the entire circumference of the left ventricle and focal areas of right ventricle (atria were not examined). Evidence of early collagen deposition was present using trichrome staining, and the resolving lesions were rich in macrophages. The acute lesions were often found along the border of the resolving lesions, but were also found as isolated groups of necrotic myocytes. Necrosis was characterized by coagulation of the cytoplasm and vacuole formation.
DISCUSSION
Exposure to aniline and substituted anilines is known to cause selective splenic toxicity in rats (Bus and Popp, 1987; Khan et ai, 1997a) . The mechanism for aniline-induced splenic toxicity is not fully elucidated. In view of potential exposure to aniline and related compounds to humans, there is a clear need to understand the mechanism(s) of this selective splenic toxicity. The focus of this study was to determine whether the splenic toxicity associated with aniline exposure is a function of its metabolite(s). This hypothesis stems from the fact that aniline does not cause methemoglobin formation when it is incubated with erythrocytes (in vitro) in concentrations associated with in vivo methemoglobinemia (Harrison and Jollow, 1987) , suggesting that the observed methemoglobinemia is mediated by a metabolite(s) formed during hepatic clearance of aniline (Kiese, 1966) . N-oxidation of aniline results in the formation of PHA, which can be further oxidized to NB (Eyer et al, 1980) . These two metabolites are interconverted in the blood via an enzyme-mediated redox cycle (Kiese, 1966) . On the other hand, ring hydroxylation in aniline results in the formation of 2-and 4-aminophenols (Kao et al, 1978) . Even though PHA is a minor metabolite of aniline, it is most potent in causing methemoglobinemia and hemolysis in vivo (Kiese, 1974; Harrison and Jollow, 1986) .
In elucidating the role of PHA in the splenic toxicity of aniline, we have addressed two main questions: (1) whether PHA can cause similar early biochemical and morphological changes which are observed with aniline and (2) its relative potency compared to that of the parent compound.
The role of PHA in aniline-induced methemoglobinemia is well established (Jenkins el al, 1972; Harrison and Jollow, 1987) . Our earlier time-course study on the formation of methemoglobin established that methemoglobin level peaks as early as 30 min following aniline administration but remains slightly higher up to 24 h (Khan et al., 1997b) . In this study, even though we measured the methemoglobin levels 24 h following the last dose of PHA, the increases in methemoglobin levels were still evident, even at the lowest dose studied, indicating a greater potential of this metabolite in inducing methemoglobinemia.
One of the important features of this study was a dosedependent increase in spleen weights (splenomegaly) of PHAtreated rats. PHA-induced splenomegaly correlates well with methemoglobin formation. Even at the lowest dose, PHA still caused a significant increase in splenic weight, whereas in the case of aniline a similar effect was observed at 1 mmoiykg or higher (Khan et al, 1997a) . The splenomegaly, presumably due to excessive deposition of PHA-modified erythrocytes, will also increase the likelihood of release of the metabolite in the red pulp during erythroclasia. The metabolite could bind with splenic mesenchymal tissues, causing injury and/or deleterious effects.
Our recent studies with aniline suggested a role for oxidative stress in splenic toxicity (Khan et al, 1997a) . PHA administration, even at the lowest dose tested, also resulted in increased lipid peroxidation, which is considered a toxic mechanism of action of several agents (Plaa and Witschi, 1976; Poli and Parola, 1996) and possibly of tumorigenesis (Comporti, 1985) . Lipid peroxidation could lead to formation of cytotoxic degradation products, including MDA and 4-hydroxy-2-nonenal (Esterbauer et al, 1991) , which are implicated in mutagenesis, tumorigenesis, and initiation and promotion of carcinogenesis (Ames, 1983; Cerutti, 1985; Comporti, 1985) . Plausable pathways in aniline-induced splenic injury have been discussed earlier (Khan et al, 1997a) . The mechanism(s) by which PHA induces lipid peroxidation is a complex issue, but it has been shown that adduction of C-nitrosoaromatics (resulting from oxidation of PHA-like structures) to polyunsaturated fatty acids yields radical species which directly and/or via reaction with iron lead to lipid peroxidation (Sammartano and Malejka-Giganti, 1991) .
Another interesting feature of this study was the PHAinduced increase in the protein carbonyl content. The measurement of protein carbonyl has not only been used as a sensitive indicator of oxidative damage to protein (Stadtman, 1990; Stadtman and Oliver, 1991) , but also has been suggested as a casual factor in oxidative injury (Ciolino and Levine, 1997) . Oxidatively modified proteins are highly susceptible to proteolysis (Davies, 1987; Stadtman, 1992) and thus could lead to perturbation of the normal functioning of the spleen. Interestingly, the increases in splenic lipid peroxidation and protein oxidation showed consistent responses and are associated with the accumulation of iron in the spleen. Although we do not know the nature and the form of iron yet, when present in free form, it may catalyze the generation of reactive oxygen species (Minotti, 1992) . These react with and damage cellular molecules leading to cellular dysfunction and toxicity.
The morphological findings in this study, especially the vascular congestion of the spleen, is consistent with our earlier observation with aniline (Khan etal, 1993 (Khan etal, , 1995a (Khan etal, , 1997a . The splenic congestion appears to be due to sludging of damaged erythrocytes, which could then become more accessible to macrophages, with possible subsequent release of a metabolite^). The sustained congestion and release of a metabolite(s) due to degradation of erythrocyte proteins could have serious consequences as the released metabolites could bind with splenic cellular components, causing structural and functional changes, leading to splenic toxicity. The histologic lesions in the hearts of high-dose PHAtreated animals were an unexpected finding. The lesions consisted of acute and chronic, or resolving, myocardial necrosis, with evidence of macrophage infiltration and collagen deposition. To the best of our knowledge, heart lesions have not been reported previously with PHA or aniline. The observed myocardial changes are similar to those produced by long-term treatment with catecholamines (Rona, 1985) and it is possible that PHA could exert positive ionotropic effects on the heart. Another, perhaps more likely, possibility is that extensive methemoglobinemia in high-dose PHA animals could induce a relative hypoxia as a result of the reduced amount of oxygen available to the myocytes. The subendocardium is a site that is very susceptible to anoxia, thus explaining the localization of lesions. In addition, an apparent mild degree of myocardial hypertrophy (24% increase in heart/body weight ratio) could also be explained by a chronic anoxic state associated with methemoglobinemia since anemia is a well-known cause of myocardial hypertrophy.
It is not clear why these cardiac lesions were not seen in aniline-treated animals. Most likely, since PHA is a minor metabolite of aniline, spleen being the main target of aniline and/or its metabolite(s), significant amounts of PHA might not have reached to the hearts of the aniline-treated animals. Thus, the cardiac toxicity observed in this study is an interesting outcome and merits a thorough investigation.
In conclusion, we have shown that PHA is a splenotoxin and therefore, can contribute to the toxicity of aniline. Our in vivo results not only show a dose-dependent splenotoxic response but also indicate that PHA even at 40-to 50-fold lower concentrations could produce effects similar to aniline. Our results further support the role of oxidative stress in the splenic toxicity of aniline, while also uncovering the heart as another potential target organ.
